Nouvelles

2018

Octobre 2018

Quality Control in the Production of Radiopharmaceuticals
Advances have led to the production of new radiopharmaceuticals and availability of new production routes. Various new diagnostic agents in the field (such as Ga-68 radiopharmaceuticals and generators) as well as therapeutic agents (such as alpha emitters) have been added to the clinician’s menu. It is essential that radiopharmaceuticals are prepared within a robust quality control system encompassing materials and personnel, with adequate documentation, and continuous review of ongoing results. This publication provides guidelines and best practices for the quality control of medical radioisotopes and radiopharmaceuticals. It was written by a group of experts with experience across a range of radiopharmaceuticals and is intended to support professionals in the preparation of good quality and safe products to be used in nuclear medicine procedures.


Juin 2018

Darlington to supply moly-99

Ontario Power Generation's (OPG) Darlington nuclear power plant is to produce molybdenum-99 (Mo-99) for use in new technetium-99m (Tc-99m) generators designed by BWX Technologies Inc. The Candu plant will be the first large-scale commercial nuclear power plant in the world to produce Mo-99.

http://www.world-nuclear-news.org/RS-Darlington-to-supply-molybdenum-99-2106187.html


Avril 2018

Mo-99 Production Activities at NTP Radioisotopes (NTP) and I-131 Supply Situation

NTP reported that it received approval from the South African Nuclear Regulator to return to normal operations through the end of June 2018. During this period, NTP will engage with the NNR to ensure continued normal operation from July 2018 onwards. NTP also stated that as a result of this approval, NTP will be in a position to manufacture I-131 to assist with the international shortage.


Mars 2018

Récipiendaire du prix Émérite 2018 

Dr John Powe, Vancouver / 

Récipiendaire du prix Eric Lepp 2018

Dre Caroline Malo Pion, Montréal


2017

Octobre 2018

Quality Control in the Production of Radiopharmaceuticals
Advances have led to the production of new radiopharmaceuticals and availability of new production routes. Various new diagnostic agents in the field (such as Ga-68 radiopharmaceuticals and generators) as well as therapeutic agents (such as alpha emitters) have been added to the clinician’s menu. It is essential that radiopharmaceuticals are prepared within a robust quality control system encompassing materials and personnel, with adequate documentation, and continuous review of ongoing results. This publication provides guidelines and best practices for the quality control of medical radioisotopes and radiopharmaceuticals. It was written by a group of experts with experience across a range of radiopharmaceuticals and is intended to support professionals in the preparation of good quality and safe products to be used in nuclear medicine procedures.


Juin 2018

Darlington to supply moly-99

Ontario Power Generation's (OPG) Darlington nuclear power plant is to produce molybdenum-99 (Mo-99) for use in new technetium-99m (Tc-99m) generators designed by BWX Technologies Inc. The Candu plant will be the first large-scale commercial nuclear power plant in the world to produce Mo-99.

http://www.world-nuclear-news.org/RS-Darlington-to-supply-molybdenum-99-2106187.html


Avril 2018

Mo-99 Production Activities at NTP Radioisotopes (NTP) and I-131 Supply Situation

NTP reported that it received approval from the South African Nuclear Regulator to return to normal operations through the end of June 2018. During this period, NTP will engage with the NNR to ensure continued normal operation from July 2018 onwards. NTP also stated that as a result of this approval, NTP will be in a position to manufacture I-131 to assist with the international shortage.


Mars 2018

Récipiendaire du prix Émérite 2018 

Dr John Powe, Vancouver / 

Récipiendaire du prix Eric Lepp 2018

Dre Caroline Malo Pion, Montréal


Juillet 2017

Beta, BTG’s Education, Training and Audit program

Beta, BTG’s Education, Training and Audit program is designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (SIRT) by increasing awareness of radiation safety and providing risk education.

For more information, click here:


IAEA Webinars and E-Learning Modules

Free IAEA Webinars and e-learning modules available

For more information, click here:



Mai 2017

Hermes - News Letter and Press Release

Introduction de notre nouveau PDG

Nous sommes ravis d’annoncer la nomination de Mikael Strindlund en tant que nouveau président et chef de la direction chez Hermes Solutions Médicales

Cliquez ici pour visionner l'info lettre.


***************************


2016

Novembre 2016


Un nouvel Accord sur la santé pour tous les Canadiens - Novembre 2016

Le rapport de la conférence - Les présentateurs et les débatteurs présents au Sommet sur la santé tenu par Canada 2020 ont formulé de nombreuses recommandations quant aux façons d’améliorer le système de santé au Canada.

Lire le rapport ici


*********************

Octobre 2016


Nos initiatives fructueuses en matière de chaîne d’approvisionnement nous ont permis de nous préparer pour la transition du réacteur national de recherche universel (NRU) à la réserve d’urgence du Mo-99 qui aura lieu le 31 octobre 2016

En Lire plus


*********************


Septembre 2016


Lettre de Lantheus concernant l'approvisionnemnt en Mo99 - 28 septembre 2016

Nos initiatives fructueuses en matière de chaîne d’approvisionnement nous ont permis de nous préparer pour la transition du réacteur national de recherche universel (NRU) à la réserve d’urgence du Mo-99 qui aura lieu le 31 octobre 2016. En collaborant étroitement avec nos fournisseurs ANSTO (Australie), IRE (Belgique) et NTP (Afrique du Sud), desquels nous obtenons déjà la plus grande partie de notre approvisionnement en Mo-99, nous avons prévu nos besoins quotidiens, hebdomadaires et mensuels en Mo-99. Nous participons régulièrement à des réunions pour examiner les besoins en approvisionnement à court et à long terme afin de coordonner notre chaîne d’approvisionnement équilibrée et diversifiée.

Lire la lettre en entier en cliquant ici.


*********************


GE Healthcare regrets to inform you that the expected return DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection) to the global market has been delayed indefinitely.  We will be unable to provide supply of DMSA to our customers until further notice.

En lire plus


*********************


Présidence - WFNMB-Presidency Bid Presidency Candidate:
Dr. Jean-Luc Urbain
En  lire plus

******************************************

Comments to USP Chapter 797-Compounding Radiopharmaceuticals-SNMMI
Read More
*********************

New seminars in the ‘Basic Nuclear Medicine’ series have been released. To access them please visit the IAEA Human Health Campus website or click on the title above. Be on the lookout for a new seminar every Monday in the Basic and Paediatric Nuclear Medicine Series.
Click Here
 

Nouvelles - archivées avant 2016

Notification Regarding Molybdenum-99 Supply Disruption from the NRU / Avis concernant une rupture d'approvisionnement de Molybdène-99 du réacteur NRU - November 23, 2013

In accordance with the Government of Canada protocol, Atomic Energy of Canada Limited (AECL) has advised Health Canada that the NRU has returned to service and resumed supplying molybdenum-99. 

Read More..., 


Avis concernant une rupture d'approvisionnement de Molybdène-99 du réacteur NRU - 23 novembre 2013

En Lire Plus.... 


CBC News - Isotope Supply - November 22, 2013
http://www.cbc.ca/news/health/medical-isotope-supply-interrupted-across-canada-1.2436964


Mise-à-jour - Approvisionnement en Mo-99 - Mallinckrodt
- 21 novembre 

Mallinckrodt Mo-99 Update 11-20-13 CN-FR.pdf

MISE À JOUR  - 19 novembre 2013 Avis concernant une rupture      d'approvisionnement de Molybdène-99 du réacteur NRU - Lettre du Dr.    Norman Laurin, Président de l’ACMN. 

MISE À JOUR  - 23 septembre 2013

Une lettre du Dr Norman Laurin en ce qui a trait à l'approvisionnement en MAA.

En lire plus…. 

Powered by Wild Apricot Membership Software